Biocon and Evotec have struck a licensing deal that will allow Biocon to expand its current basket of biosimilars beyond diabetes, oncology and immunology, in exchange for licensing and milestone payments to Evotec.
Biocon Biologics and Evotec subsidiary Just-Evotec Biologics have struck a licensing deal for an early-stage, pre-clinical biosimilar asset.
Biocon will take the undisclosed biosimilar asset through end-to-end development – including investigational new drug filing, manufacturing and commercialization post-regulatory...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
